AU583568B2 - Improved pharmaceutical composition containing 13-cis vitamin A acid as the active ingredient - Google Patents

Improved pharmaceutical composition containing 13-cis vitamin A acid as the active ingredient

Info

Publication number
AU583568B2
AU583568B2 AU51226/85A AU5122685A AU583568B2 AU 583568 B2 AU583568 B2 AU 583568B2 AU 51226/85 A AU51226/85 A AU 51226/85A AU 5122685 A AU5122685 A AU 5122685A AU 583568 B2 AU583568 B2 AU 583568B2
Authority
AU
Australia
Prior art keywords
composition
weight
acid
cis vitamin
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU51226/85A
Other languages
English (en)
Other versions
AU5122685A (en
Inventor
Paul J. Jarosz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of AU5122685A publication Critical patent/AU5122685A/en
Application granted granted Critical
Publication of AU583568B2 publication Critical patent/AU583568B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU51226/85A 1984-12-14 1985-12-13 Improved pharmaceutical composition containing 13-cis vitamin A acid as the active ingredient Ceased AU583568B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68197084A 1984-12-14 1984-12-14
US681970 2001-07-02

Publications (2)

Publication Number Publication Date
AU5122685A AU5122685A (en) 1986-07-17
AU583568B2 true AU583568B2 (en) 1989-05-04

Family

ID=24737639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51226/85A Ceased AU583568B2 (en) 1984-12-14 1985-12-13 Improved pharmaceutical composition containing 13-cis vitamin A acid as the active ingredient

Country Status (9)

Country Link
EP (1) EP0184942B1 (enExample)
JP (1) JPS61145114A (enExample)
AT (1) ATE55247T1 (enExample)
AU (1) AU583568B2 (enExample)
CA (1) CA1282326C (enExample)
DE (1) DE3579128D1 (enExample)
DK (1) DK581185A (enExample)
GR (1) GR852997B (enExample)
PH (1) PH21591A (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5175002A (en) * 1991-10-02 1992-12-29 Du Pont Merck Pharmaceutical Company Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
DE19603402A1 (de) * 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
IN192188B (enExample) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
ES2225600T3 (es) * 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
BR0117191A (pt) * 2001-12-06 2005-05-10 Ranbaxy Lab Ltd Composições nanoparticuladas de isotretinoina
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010109259A1 (es) * 2009-03-26 2010-09-30 Grufarcol Ltda Métoda para preparar formulaciones de gel blando de isotretinoína líquida y la formulaciones obtenidas
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
SG176096A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Liquid dosage forms of isotretinoin
EP2432453A2 (en) 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Topical retinoid solutions
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
ES2661812T3 (es) 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
WO2019205030A1 (zh) * 2018-04-25 2019-10-31 人福普克药业（武汉）有限公司 盐酸金刚烷胺软胶囊及其制备方法
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) * 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
US4464394A (en) * 1970-06-23 1984-08-07 Hoffmann Laroche Inc. Compositions and methods for using 13-cis vitamin A acid compounds
AU4083685A (en) * 1984-04-02 1985-10-10 F. Hoffmann-La Roche Ag Pharmaceutical compositions of 4-oxo or 4-hydroxy-13-cis-vitamin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124510A (en) * 1964-03-10 Stable dry powdered fat-soluble
GB1590864A (en) * 1978-05-16 1981-06-10 Lilly Industries Ltd Thixotropic filling medium for hard gelatin capsules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464394A (en) * 1970-06-23 1984-08-07 Hoffmann Laroche Inc. Compositions and methods for using 13-cis vitamin A acid compounds
US4322438A (en) * 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
AU4083685A (en) * 1984-04-02 1985-10-10 F. Hoffmann-La Roche Ag Pharmaceutical compositions of 4-oxo or 4-hydroxy-13-cis-vitamin

Also Published As

Publication number Publication date
EP0184942A2 (en) 1986-06-18
JPS61145114A (ja) 1986-07-02
EP0184942B1 (en) 1990-08-08
EP0184942A3 (en) 1987-08-05
DK581185D0 (da) 1985-12-13
DE3579128D1 (de) 1990-09-13
AU5122685A (en) 1986-07-17
PH21591A (en) 1987-12-11
ATE55247T1 (de) 1990-08-15
DK581185A (da) 1986-06-15
CA1282326C (en) 1991-04-02
GR852997B (enExample) 1986-04-16

Similar Documents

Publication Publication Date Title
AU5122685A (en) Improved pharmaceutical composition containing 13-cis vitamin A acid as the active ingredient
AU614726B2 (en) Substituted alpha-amino acids, their preparation and pharmaceutical compositions containing them
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
WO1987003480A3 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
AU4936890A (en) Medicament containing dihydrolipoic acid as active substance
IL76133A (en) Mercaptomethyl-octahydro-oxo-pyridazino(1,2-a)(1,2)diazepine-,diazocine-and(1,2,5)triazepinecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them and certain intermediates therefor
AU5354286A (en) Pyrethroidal composition comprising more than one active ingredients
EP0215596A3 (en) Composition for injection of active type vitamins d3
GR3006426T3 (enExample)
AU4538489A (en) Pharmaceutical compositions
IL74734A0 (en) Substituted alpha-amino acids,their preparation and pharmaceutical compositions containing them
AU5425886A (en) Anticalculus oral composition containing phosphonoformic acid
AU569176B2 (en) Preparation of 2,4-dichloro-5-fluoro-benzoic acid
ATE78693T1 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
AU556498B2 (en) Preparation of 5,6,7,8-tetrahydrofolic acid
ES8800217A1 (es) Procedimiento para la preparacion de acidos 4-(isoxazolil)-tiazol-2-oxamicos y sus derivados
AU5643686A (en) Novel carboxylic acid esters, methods for production thereof and insecticides containing them as the active ingredient
HUT41211A (en) Insecticide compositions containing alkane derivatives as active substances and process for preparing the active ingredients
IE872239L (en) Pyridopyrimidinediones and quinazolines
EP0226842A3 (en) Substituted 1,4-naphthalenediones, processes for their preparation and pharmaceutical compositions containing them
AU565647B2 (en) Stabilized anthelmintic formulations
EP0175377A3 (en) An ether compound, its production and an insecticidal and acaricidal composition containing it as an active ingredient
WO1987003590A1 (fr) Medicament pour le traitement des maladies du foie
DE3660806D1 (en) Novel compound, its production and insecticidal and acaricidal composition containing it as an active ingredient
AU579718B2 (en) Substituted 1,8-naphthyridionones, processes for their preparation and pharmaceutical compositions containing them